Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [2] - The company's lead program, Zumilokibart (APG777), is primarily aimed at treating AD, which is identified as the largest and least penetrated market within I&I [2] - Apogee's antibody programs are designed to enhance efficacy and dosing by targeting established mechanisms of action and utilizing advanced antibody engineering to improve properties such as half-life [2] Upcoming Events - Management of Apogee Therapeutics will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 p.m. E.T. [1] - A live and archived webcast of the event will be accessible on the company's website under the Investors section [1]